bezuclastinib
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Systemic Mastocytosis (AdvSM)
Conditions
Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
Trial Timeline
Nov 9, 2021 → Jul 1, 2026
NCT ID
NCT04996875About bezuclastinib
bezuclastinib is a phase 2 stage product being developed by Cogent Biosciences for Advanced Systemic Mastocytosis (AdvSM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT04996875. Target conditions include Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL).
What happened to similar drugs?
16 of 20 similar drugs in Advanced Systemic Mastocytosis (AdvSM) were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06915766 | Pre-clinical | Active |
| NCT04996875 | Phase 2 | Recruiting |
Competing Products
20 competing products in Advanced Systemic Mastocytosis (AdvSM)